Drug Sponsors

pSivida plans to consolidate all R&D in current U.S. facility

Wednesday, July 27, 2016

pSivida, a leader in the development of sustained release drug delivery products primarily for eye diseases, is implementing a site consolidation plan in support of its product development program and plans to conduct all future research and product development in a single location. Subject to an employee consultation process required by local U.K. law, pSivida proposes to close its research facility in Malvern, U.K. and locate all research and product development activities in the company’s state-of-the-art, cGMP facility in Watertown, Massachusetts.

[Read More]

EMD Serono to open $115M life science campus in Massachusetts

Tuesday, July 19, 2016

EMD Serono, known as Merck outside of the U.S. and Canada, a science and technology company, has announced plans to build a new campus in Burlington, Massachusetts, that will serve as a major hub for the North American life science business of Merck. The 280,000-square-foot facility will include a customer collaboration laboratory and training center as well as office space.

[Read More]

Bristol-Myers Squibb acquires Cormorant Pharmaceuticals

Tuesday, July 5, 2016

Bristol-Myers Squibb has acquired all of the outstanding capital stock of Cormorant Pharmaceuticals, a private, Stockholm, Sweden-based pharmaceutical company focused on the development of therapies for cancer and rare diseases. The acquisition gives Bristol-Myers Squibb full rights to Cormorant’s HuMax-IL8 antibody program and the lead candidate HuMax-IL8, a phase I/II monoclonal antibody targeted against interleukin-8 (IL-8) that represents a potentially complementary immuno-oncology mechanism of action to T-cell directed antibodies and co-stimulatory molecules.

[Read More]

Biogen selects Cognizant’s SmartTrials Platform

Friday, July 1, 2016

Biogen has selected Cognizant‘s SmartTrials platform to aggregate and store clinical trial operational and patient data. Cambridge, Mass.-based Biogen has a portfolio of medicines to treat multiple sclerosis (MS) and is at the forefront of neurology research, working to develop novel therapies for conditions with few or no treatment options.

[Read More]